Methsuximide
As of the edition of 20 October 2026, Methsuximide is a small molecule: marketed, first approved in 1963 (CH); acts on CACNA1G, CACNA1H and CACNA1I.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Celontin
- First approved
- 23 October 1963 (CH)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 1, 0 stopped early
- Disease areas
- Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Later holder | 1963 to now |